CA125 and HE4 levels in a Czech Female Population Diagnosed with Endometrial Cancer in Preoperative Management

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10227295" target="_blank" >RIV/00216208:11110/14:10227295 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/14:10227295 RIV/00669806:_____/14:10227295

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

CA125 and HE4 levels in a Czech Female Population Diagnosed with Endometrial Cancer in Preoperative Management

Popis výsledku v původním jazyce

Aim: The aim of the present study was to compare the use of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) biomarkers in patients with endometrial cancer for preoperative management and to particularly focus on relationship between CA125and HE4 and disease stage in predicting myometrial invasion or intrauterine tumor spread. Patients and Methods: Thirty-four patients diagnosed with endometrial cancer and 32 healthy controls were enrolled into the pilot study in the period between May 2012 and March 2013. Blood from all the females was collected and examined for CA125 and HE4. Based on standardized ultrasound examination, including gynecological examination, the clinical disease stage was determined. Results: We found a significant difference (p<0.0001) for means of serum levels of HE4: females with endometrial cancer, 75.5 pmol/l, versus healthy females, 40.0 pmol/l. A non-significant statistical difference was found for mean serum CA125 levels (p=0.4442): females wit

Název v anglickém jazyce

CA125 and HE4 levels in a Czech Female Population Diagnosed with Endometrial Cancer in Preoperative Management

Popis výsledku anglicky

Aim: The aim of the present study was to compare the use of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) biomarkers in patients with endometrial cancer for preoperative management and to particularly focus on relationship between CA125and HE4 and disease stage in predicting myometrial invasion or intrauterine tumor spread. Patients and Methods: Thirty-four patients diagnosed with endometrial cancer and 32 healthy controls were enrolled into the pilot study in the period between May 2012 and March 2013. Blood from all the females was collected and examined for CA125 and HE4. Based on standardized ultrasound examination, including gynecological examination, the clinical disease stage was determined. Results: We found a significant difference (p<0.0001) for means of serum levels of HE4: females with endometrial cancer, 75.5 pmol/l, versus healthy females, 40.0 pmol/l. A non-significant statistical difference was found for mean serum CA125 levels (p=0.4442): females wit

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/EE2.3.20.0040" target="_blank" >EE2.3.20.0040: Molekulární genetika nádorových a kardiovaskulárních chorob</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

1A

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

5

Strana od-do

327-331

Kód UT WoS článku

000329765300044

EID výsledku v databázi Scopus

—